BCM
STLN

Basso Capital Management’s Starling Oncology STLN Stock Holding History

Basso Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-145,485
Closed -$1.46M – 189
2020
Q2 		$1.46M Buy
+145,485
New +$1.45M 0.46% 68

Other funds holding STLN

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Basso Capital Management's STLN Position: Q3 2020 in Review

Basso Capital Management sold out of Starling Oncology (STLN) in Q3 2020, closing a stake of 145,485 shares — an estimated $1.46M sold.

Basso Capital Management first reported a position in STLN in Q2 2020 and held it in 1 quarter. The position peaked at $1.46M in Q2 2020. 38 funds tracked by Wall St. Rank hold STLN as of Q3 2020.

  • Basso Capital Management reported no remaining Starling Oncology position as of Q3 2020 after selling out during the quarter.
  • Basso Capital Management sold 145,485 Starling Oncology shares in Q3 2020, an estimated $1.46M.
  • Basso Capital Management first reported a position in Starling Oncology in Q2 2020 and held it in 1 quarter.
  • Basso Capital Management's Starling Oncology position peaked at $1.46M in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2020.

Based on Basso Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.